Heidelberg University

At Heidelberg University the focus is on developing new therapies that lower the risk of heart attacks, strokes and other vascular events, aiming to improve long‑term survival and quality of life for patients with cardiovascular conditions.

• Acute Coronary Syndrome
• Atherosclerotic cardiovascular disease (ASCVD)
• Acute ischemic stroke
• Intermediate‑high‑risk pulmonary embolism
• Hypercholesterolemia
• Adults at high risk of cardiovascular events without prior MI or stroke

More than 20 clinical trials are active in this therapeutic area, supported by a dedicated team of investigators working to evaluate safety and efficacy of innovative cardiovascular agents.

Researchers are testing novel biologics and small molecules to control inflammation and restore intestinal health, with the goal of achieving durable remission for patients with chronic gut disorders.

• Crohn’s Disease
• Ulcerative Colitis
• Fistulizing perianal Crohn’s Disease
• Celiac Disease
• Chronic Hepatitis B Virus Infection
• Gastrointestinal stromal tumor

Approximately 15 trials explore therapeutic options ranging from immune‑modulating antibodies to targeted agents, with a multidisciplinary team of gastroenterology and oncology specialists.

The department conducts extensive studies on blood‑cancer therapies, seeking to improve remission rates and reduce treatment‑related toxicity for patients with leukemias, lymphomas and related disorders.

• Acute lymphoblastic leukemia (Ph+)
• Acute myeloid leukemia
• Chronic myeloid leukemia
• Myelodysplastic Syndromes (MDS)
• Multiple myeloma
• Primary mediastinal large B‑cell lymphoma (PMBCL)
• Advanced systemic mastocytosis

Over 25 trials evaluate targeted inhibitors, combination regimens and cellular therapies, driven by a cohort of hematology experts.

Studies aim to modulate aberrant immune responses, offering patients safer and more effective options for autoimmune and inflammatory conditions.

• Lupus Nephritis (LN)
• Immunoglobulin A Nephropathy (IgAN)
• Hypereosinophilic Syndrome (HES)
• Relapsing Remitting Multiple Sclerosis (RRMS)
• Secondary progressive multiple sclerosis

Around 10 trials focus on biologics, complement inhibitors and novel small molecules, with close collaboration between rheumatology, nephrology and neurology units.

A broad oncology program evaluates cutting‑edge treatments—including immunotherapies, antibody‑drug conjugates and precision‑targeted agents—to extend survival across a wide spectrum of solid tumours.

• Breast Cancer (HER2‑positive, HER2‑negative, triple‑negative)
• Non‑Small‑Cell Lung Cancer
• Metastatic Melanoma
• Colorectal Cancer
• Gastric and gastro‑esophageal junction adenocarcinoma
• Ovarian Cancer
• Prostate Cancer (castration‑sensitive)
• Urothelial Carcinoma
• Pancreatic Cancer
• Merkel Cell Carcinoma

More than 30 active trials investigate efficacy and safety of novel regimens, with a strong emphasis on biomarker‑driven patient selection.

Clinical investigations target neurodegeneration and brain tumours, striving to slow disease progression and improve neurological function through innovative therapeutic approaches.

• Amyotrophic Lateral Sclerosis (ALS)
• Alzheimer’s disease (mild cognitive impairment)
• Glioblastoma
• IDH‑mutant glioma
• Medulloblastoma

Approximately 12 trials explore gene‑targeted drugs, immunotherapies and neuroprotective agents, supported by specialized neuro‑oncology and neurology teams.

Research seeks to treat metabolic liver disease and obesity, evaluating agents that can reverse fibrosis and reduce cardiovascular risk associated with metabolic dysfunction.

• Non‑alcoholic steatohepatitis (NASH)
• Obesity
• Overweight
• Hypercholesterolemia
• Diabetes (related complications)

Ten trials are currently enrolling patients to assess efficacy of novel metabolic modulators and lifestyle‑integrated interventions.

The site evaluates therapies that reduce clot burden and improve pulmonary outcomes in acute vascular events affecting the lungs.

• Intermediate‑high‑risk acute pulmonary embolism
• Acute ischemic stroke with atrial fibrillation (cardio‑embolic component)

A focused program of 5 trials examines reduced‑dose thrombolysis and anticoagulant strategies, aiming to balance efficacy with safety.

Efforts concentrate on targeted and immune‑based treatments for aggressive skin cancers, with the objective of achieving deeper responses and lasting remission.

• Advanced Melanoma
• Cutaneous Melanoma (relapsed/refractory)
• Merkel Cell Carcinoma
• Desmoid tumours/aggressive fibromatosis

About 8 trials test checkpoint inhibitors, antibody‑drug conjugates and pathway‑specific inhibitors in these malignancies.

Investigations aim to control chronic viral infections and prevent disease progression through antiviral and immunomodulatory strategies.

• Chronic Hepatitis B Virus Infection
• Viral‑associated liver disease (FGFR2b‑positive adenocarcinoma)

Four clinical studies assess novel antivirals and combination regimens to achieve viral suppression and improve liver outcomes.